Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Accumulated Expenses (2021 - 2022)

Senti Biosciences has reported Accumulated Expenses over the past 2 years, most recently at $4.0 million for Q1 2022.

  • For Q1 2022, Accumulated Expenses rose 396732.4% year-over-year to $4.0 million; the TTM value through Mar 2022 reached $4.0 million, up 396732.4%, while the annual FY2021 figure was $3.1 million, N/A changed from the prior year.
  • Accumulated Expenses for Q1 2022 was $4.0 million at Senti Biosciences, up from $3.1 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $4.0 million in Q1 2022 and troughed at $1000.0 in Q1 2021.